Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
Holding EVO?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.04Last Year’s EPS
-$0.05Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -2.40%
|Next Earnings Date:Mar 27, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Evotec SE. While there were significant achievements in the Just - Evotec Biologics segment with substantial revenue growth and strong liquidity, challenges persist in the Shared R&D segment with revenue declines and reduced margins. The company is focusing on cost optimization and has promising partnerships, but profitability remains under pressure.Company Guidance
During the EVT.DE Q1 2024 earnings call, Evotec provided detailed guidance despite the challenging market conditions. The company reported a 2% decrease in revenue to EUR 208.8 million compared to the same period in 2023, largely due to a 23% decline in the Shared R&D segment. However, Just - Evotec Biologics achieved a remarkable 380% increase, reaching EUR 53.5 million in revenue. The gross margin declined to 17% from 25%, influenced by high fixed costs and capacity ramp-up. R&D expenses were reduced from EUR 18.5 million to EUR 16.2 million, aligning with strategic priorities. Adjusted Group EBITDA fell by 73% to EUR 7.8 million. The company highlighted a 70% increase in Discovery sales, indicating a potential recovery in the latter half of 2024. Despite challenges, Evotec maintains a strong financial position with over EUR 500 million in liquidity, preparing for future growth with strategic partnerships and operational improvements.Just - Evotec Biologics Revenue Growth
The Just - Evotec Biologics segment achieved EUR 53.5 million in revenue in Q1, marking a growth of over 380% compared to the same period last year, driven by collaborations with Sandoz and the Department of Defense.
Discovery Sales Recovery
The Discovery sales book increased by 70%, indicating a potential revenue recovery in the second half of 2024.
Strong Financial Liquidity
Evotec reported over EUR 500 million in liquidity at the end of Q1, providing financial flexibility despite challenging conditions.
Partnerships and Collaborations
Notable partnerships include an AI-powered strategic partnership with Owkin and a precision medicine collaboration in cardiology with Bayer.
---
EVO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EVO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $4.58 | $3.86 | -15.72% |
| Aug 14, 2024 | $3.32 | $3.31 | -0.30% |
| May 22, 2024 | $5.09 | $5.17 | +1.57% |
| Apr 24, 2024 | $7.65 | $5.23 | -31.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Evotec AG (EVO) report earnings?
Evotec AG (EVO) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Evotec AG (EVO) earnings time?
Evotec AG (EVO) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVO EPS forecast?
EVO EPS forecast for the fiscal quarter 2024 (Q4) is -$0.04.
---